Abstracts tagged "interferons"

Abstract Number: 105 • 2018 ACR/ARHP Annual Meeting
Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
Majid Zeidi^1,2, Krisha Desai^3,4, Hee Joo Kim^3,4,5 and Victoria P. Werth^3,4, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Department of Dermatology, Gachon Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea, Republic of (South)
Background/Purpose: Two major therapies for cutaneous lupus erythematosus (CLE) are the antimalarials, hydroxychloroquine (HCQ) and quinacrine (QC). HCQ is often the first-line therapy for CLE,…
Abstract Number: 125 • 2018 ACR/ARHP Annual Meeting
Monocyte Transcriptome Delineates SSc Patients with Functionally Distinct Patterns of Gene Dysregulation That Persist through Differentiation
Julia L.M. Dunn¹, Philip J. Homan², Salina Dominguez¹, Carla M. Cuda¹, Kathleen Aren³, Mary A. Carns^3,4, Tracy M. Frech⁵, Dinesh Khanna⁶, Shervin Assassi⁷, Harris Perlman¹, Monique Hinchcliff¹ and Deborah R. Winter¹, ¹Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁷Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: The etiology and pathogenesis of SSc are poorly understood; however, an increasing body of evidence supports an early inflammatory phase that precedes, and may…
Abstract Number: 878 • 2018 ACR/ARHP Annual Meeting
IFN Level Assessed By Ultrasensitive Detection Technology in Myositis Patient: A Promising Biomarker of Disease Activity in Dermatomyositis and Anti-Synthetase Syndrome
Loïs BOLKO^1,2, Ségolène Toquet³, Océane Landon-Cardinal⁴, Karim DORGHAM⁵, Celine Anquetil⁶, Darragh Duffy⁷, Nadège WESNER⁸, Damien Amelin⁹, Gaëlle DZANGUE TCHOUPOU², Perrine Guillaume¹⁰, Aude Rigolet¹¹, Baptiste Hervier¹¹, Mathieu Vautier¹¹, Nicolas Champtiaux¹¹, Guy Gorochov¹², Jean-Hugues Salmon¹³, Olivier Benveniste¹¹ and Yves Allenbach¹⁴, ¹Rheumatology, CHU Reims, Hôpital Maison Blanche, Reims, France, ²INSERM UMRS974, Pitié-Salpêtrière University Hospital, Paris, France, ³Médecine interne, CHU Reims, Robert debré, Reims, France, ⁴Rhumatologie, Hopital Notre-Dame Montréal, Montreal, QC, Canada, ⁵CIMI, INSERM, Paris, France, ⁶CDR en myologie UMR974,, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, PARIS, France, ⁷Institut Pasteur, Paris, Paris, France, ⁸INSERM UMRS974, Pitié-Salpêtrière University Hospital, paris, France, ⁹Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ¹⁰Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié Salpêtrière, paris, France, ¹¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ¹²CIMI, INSERM, paris, France, ¹³Service de Rhumatologie, CHU Reims, Hôpital Maison Blanche, Reims, France, ¹⁴Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Inflammatory idiopathic myopathies (IIM) is a heterogeneous group of disorders ranging from muscle specific auto-immune diseases to systemic ones (dermatomyositis (DM), anti-synthetase syndrome (ASS),…
Abstract Number: 1080 • 2018 ACR/ARHP Annual Meeting
Hypomethylation of STAT1 and HLA-DRB1 in CD8+ T Cells Is Associated with Type-I Interferon-Dependent HLA-DRB1 Overexpression and Activation of Autologous CD4+ T Cells in Systemic Lupus Erythematosus
Shaylynn Miller¹, Patrick Coit¹, Elizabeth Gensterblum-Miller¹, Paul Renauer^1,2, Nathan Kilian^1,3, Mark Schonfeld¹, Pei-Suen Tsou¹ and Amr H Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Genetics, Yale University, New Haven, CT, ³Medical School, Georgetown University, Washington, DC
Background/Purpose: Systemic lupus erythematosus is a chronic autoimmune disease characterized by epigenetic dysregulation, and increased autoantibody and type-I interferon (IFN) production. The goal of this…
Abstract Number: 1093 • 2018 ACR/ARHP Annual Meeting
Serologic Evidence Linking Epstein Barr Virus Reactivation, Heightened Interferon Pathway Activation and Increased Disease Activity in Patients with Systemic Lupus Erythematosus
Rebecca Wood¹, Lauren Guthridge¹, Carla J. Guthridge², Rebecka L. Bourn¹, Hua Chen¹, Wade DeJager¹, Susan R. Macwana¹, Stan Kamp¹, Rufei Lu^1,3, Cristina Arriens¹, Eliza Chakravarty¹, Katherine Thanou¹, Joan T. Merrill¹, Joel M. Guthridge^1,4 and Judith A. James^4,5, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a clinically heterogeneous disease oftentimes characterized by a waxing and waning course. Mechanisms of SLE flare remain elusive. This study examined relationships…
Abstract Number: 1096 • 2018 ACR/ARHP Annual Meeting
Unexpected Association between Health-Related Quality of Life and the Blood Interferon Modular Transcriptional Signatures in Patients with Systemic Lupus Erythematosus
Laurent Chiche¹, julie seguier², stephanie gentile², stephane burtey², bertrand dussol², philippe halfon³, wahiba bidaut³, elisabeth jouve² and Noémie Jourde-Chiche⁴, ¹Internal medicine, Hopital europeen, Marseille, France, ²aphm, marseille, France, ³hopital europeen, marseille, France, ⁴Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France
Background/Purpose: SLE has important effects on health-related quality of life (HRQOL) and is not well correlated to disease activity. As most SLE patients in remission…
Abstract Number: 1111 • 2018 ACR/ARHP Annual Meeting
CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis
Clarissa Corinaldesi¹, Yasser M El-Sherbiny², Gemma Migneco³, Rebecca Ross¹, Steve Holmes⁴, Clive McKimmie⁵ and Francesco Del Galdo¹, ¹Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, ³Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom, ⁴Capella Biosciences, LTD, London, United Kingdom, ⁵Virus Host Interactions Team, Section of Infection and Immunity, University of Leeds, Leeds, United Kingdom
Background/Purpose: Human plasmacytoid dendritic cells (pDCs) have been implicated in the pathogenesis of Systemic Sclerosis (SSc) through their ability to infiltrate the skin and secrete…
Abstract Number: 1348 • 2018 ACR/ARHP Annual Meeting
Quantitative High Throughput Screening of Small Molecules to Inhibit Interferon-Stimulated Major Histocompatibility Complex Class I in Myositis Muscle
Travis Kinder, Patricia Dranchak and James Inglese, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD
Background/Purpose: Common molecular and histological features of idiopathic inflammatory myopathies (myositis) include activation of the type 1 interferon (IFN) response and aberrant expression of major…
Abstract Number: 1352 • 2018 ACR/ARHP Annual Meeting
Low Density Granulocytes in Idiopathic Inflammatory Myopathy
David Fernandez¹, Linjia Jia², Mikhail Olferiev³, Annel M. Fernandez⁴, JoAnn Vega⁵, Kerri Merritt⁶, Michael Lockshin⁷ and Peggy Crow¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ⁴Medicine- Rheumatology/ Research, Hospital for Special Surgery, New York, NY, ⁵Medicine - Rheumatology / Research, Hospital for Special Surgery, New York, NY, ⁶Hospital for Special Surgery, New York, NY, ⁷Barbara Volcker Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Idiopathic Inflammatory Myopathy (IIM) is a group of autoimmune diseases characterized by immune-mediated injury to skeletal muscle, including polymyositis (PM) and dermatomyositis (DM). Recent…
Abstract Number: 2097 • 2018 ACR/ARHP Annual Meeting
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease Severity and Alters Immune Cell Subsets in the NZB/W F1 Murine Model of Lupus
Pei Han¹, Christopher Pohlmeyer¹, Ching Shang¹, Zhihua Cui², David Lopez³, Astrid Clarke², Randall Jones², Nevena Mollova³, Igor Mikaelian⁴, David Newstrom³, Shiva Zaboli³, Allyson Shauf³ and Julie Di Paolo⁵, ¹Immunology and Inflammation, Gilead Sciences, Foster City, CA, ²Gilead Sciences, Seattle, WA, ³Gilead Sciences, Foster City, CA, ⁴Biology Core Support, Gilead Sciences, Foster City, CA, ⁵Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: SLE is a heterogeneous autoimmune disease characterized by immune system hyper-activation leading to the production of autoantibodies and immune attack on multiple organs including…
Abstract Number: 2121 • 2018 ACR/ARHP Annual Meeting
Serum High Type I Interferon Is Associated with Active Proliferative Lupus Nephritis in Lupus Patients Accompanied with High Interferon Signature Gene Expression and Plasmacytoid Dendritic Cell Infiltration in Lupus Nephritis Kidney
Taro Iwamoto¹, Jessica M. Dorschner², Mark A. Jensen¹, Shanmugapriya Selvaraj³, Danielle Vsetecka², Shreyasee Amin², Ashima Makol², Floranne C. Ernste², Thomas Osborn², Kevin Moder², Vaidehi R. Chowdhary², Valeria Mezzano⁴, Peter M. Izmirly⁵, H. Michael Belmont⁵, Robert M. Clancy¹, Jill P. Buyon¹, Ming Wu³, Cynthia A. Loomis³ and Timothy B. Niewold¹, ¹Colton Center for Autoimmunity, New York University, New York, NY, ²Mayo Clinic College of Medicine, Rochester, MN, ³Department of Pathology, New York University, New York, NY, ⁴Division of Cardiology, New York University, New York, NY, ⁵Division of Rheumatology, New York University, New York, NY
Background/Purpose: Despite recent advancements in immunosuppressive therapies, lupus nephritis (LN) remains one of the most severe organ manifestations in systemic lupus erythematosus (SLE). High type…
Abstract Number: 2592 • 2017 ACR/ARHP Annual Meeting
Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers
Raj Tummala¹, Tomas Rouse², Anna Berglind² and Linda Santiago³, ¹AstraZeneca, Gaithersburg, MD, ²AstraZeneca, Gothenberg, Sweden, ³MedImmune, LLC, Mountain View, CA
Background/Purpose: Anifrolumab is a fully human anti–interferon-ɑ receptor 1 monoclonal antibody in Phase III development as an intravenous (IV) therapeutic for systemic lupus erythematosus (SLE).…
Abstract Number: 2601 • 2017 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation in SLE Patient PBMC and in Trex1-/- Mouse Spleen and Heart
Jie An¹, Weinan Lai^2,3, Joshua Woodward⁴, Xizhang Sun¹, Lena Tanaka¹, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Medicine/Division of Rheumatology, University of Washington, Seattle, WA, ³Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁴Department of Microbiology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: Type I interferon (IFN-I) is strongly implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE) as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres…
Abstract Number: 2816 • 2017 ACR/ARHP Annual Meeting
Prediction of Connective Tissue Disease in an at-Risk Cohort Using a Novel Interferon Stimulated Gene Expression Score
Md Yuzaiful Md Yusof^1,2, Yasser M El-Sherbiny^1,3, Antonios Psarras¹, Elizabeth M.A. Hensor^1,4, Adewonuola Alase¹, Alaa Mohamed¹, Miriam Wittmann^1,4, Paul Emery^1,4 and Edward M Vital^1,4, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Prediction of connective tissue disease in an at-risk cohort using a novel interferon stimulated gene expression scoreBackground/Purpose: A period of ANA positivity and other immune…
Abstract Number: 2828 • 2017 ACR/ARHP Annual Meeting
A Graph-Theoretic-Approach Applied to Modular-Repertoire-Analysis Identifies Shared Gradual Whole Blood Interferon Signatures in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome Patients and Reveals New Interferon-Related Modules in Disease Progression
Ilya Korsunski¹, Noémie Jourde-Chiche², Peter Gregersen³, Damien Chaussabel⁴, Laurent Chiche⁵ and Naomi I. Maria⁶, ¹Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²Nephrology, AP-HM, Department of Nephrology, CHU Conception, Marseille, France, ³Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute for Med Res, Manhasset, NY, ⁴Translational Medicine, Sidra Medical and Research Center, Doha, Qatar, ⁵Internal medicine, Hopital europeen, Marseille, France, ⁶Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: There is significant clinical and molecular heterogeneity among patients suffering from systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) and primary Sjögren’s Syndrome…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].